| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/J.JAD.2019.04.018 |
| P698 | PubMed publication ID | 31004825 |
| P50 | author | Greg Rhee | Q38799776 |
| Robert A. Rosenheck | Q21094933 | ||
| P2860 | cites work | Clinical Epidemiology of Single Versus Multiple Substance Use Disorders: Polysubstance Use Disorder | Q38625841 |
| Potentially Inappropriate Antidepressant Prescriptions Among Older Adults in Office-Based Outpatient Settings: National Trends from 2002 to 2012. | Q38668808 | ||
| Effects of depression screening on diagnosing and treating mood disorders among older adults in office-based primary care outpatient settings: An instrumental variable analysis | Q38834718 | ||
| Efficacy and acceptability of atypical antipsychotics for the treatment of post-traumatic stress disorder: a meta-analysis of randomized, double-blind, placebo-controlled clinical trials | Q39160948 | ||
| Reducing polypharmacy: evidence from a simple quality improvement initiative | Q44019244 | ||
| Increased risk among older veterans of prescribing psychotropic medication in the absence of psychiatric diagnoses | Q44907573 | ||
| Adult Utilization of Psychiatric Drugs and Differences by Sex, Age, and Race. | Q45048745 | ||
| A Change in Perspective: From Dual Diagnosis to Multimorbidity | Q47597205 | ||
| Efficacy of Quetiapine Monotherapy in Posttraumatic Stress Disorder: A Randomized, Placebo-Controlled Trial | Q47982231 | ||
| Combining medications to enhance depression outcomes (CO-MED): acute and long-term outcomes of a single-blind randomized study. | Q48878233 | ||
| National Prescribing Trends for High-Risk Anticholinergic Medications in Older Adults. | Q52628767 | ||
| Polypharmacy: when is it rational? | Q80112030 | ||
| Polypharmacy in children and adolescents treated for major depressive disorder: a claims database study | Q83294329 | ||
| Antipsychotic Prescriptions Among Adults With Major Depressive Disorder in Office-Based Outpatient Settings: National Trends From 2006 to 2015 | Q87846465 | ||
| A brief history of the development of antidepressant drugs: from monoamines to glutamate | Q27028050 | ||
| American Geriatrics Society 2015 Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults | Q28268234 | ||
| The increasing use of polypharmacotherapy for refractory mood disorders: 22 years of study | Q33850634 | ||
| National trends in psychotropic medication polypharmacy in office-based psychiatry | Q34090959 | ||
| National Trends in Child and Adolescent Psychotropic Polypharmacy in Office-Based Practice, 1996-2007 | Q34187891 | ||
| Physician intervention for medication reduction in a nursing home: the polypharmacy outcomes project. | Q35007468 | ||
| Diagnosis and definition of treatment-resistant depression | Q35111568 | ||
| Sleep disorders as core symptoms of depression | Q35237012 | ||
| SSRIs versus non-SSRIs in post-traumatic stress disorder: an update with recommendations | Q35669835 | ||
| Trends in psychotropic polypharmacy among youths enrolled in Ohio Medicaid, 2002-2008 | Q35962531 | ||
| When is antipsychotic polypharmacy supported by research evidence? Implications for QI. | Q37306729 | ||
| Polypharmacy prevalence rates in the treatment of unipolar depression in an outpatient clinic | Q37356659 | ||
| Sleep disturbances: core symptoms of major depressive disorder rather than associated or comorbid disorders | Q37634504 | ||
| Is unrecognized bipolar disorder a frequent contributor to apparent treatment resistant depression? | Q37775167 | ||
| A review of atypical antipsychotic medications for posttraumatic stress disorder | Q37877514 | ||
| Atypical antipsychotic augmentation strategies in the context of guideline-based care for the treatment of major depressive disorder | Q38109590 | ||
| On 'polypharmacy' and multi-target agents, complementary strategies for improving the treatment of depression: a comparative appraisal | Q38110358 | ||
| History, background, concepts and current use of comedication and polypharmacy in psychiatry. | Q38138638 | ||
| Effect of Antidepressant Switching vs Augmentation on Remission Among Patients With Major Depressive Disorder Unresponsive to Antidepressant Treatment: The VAST-D Randomized Clinical Trial | Q38374198 | ||
| Adjunctive risperidone treatment for antidepressant-resistant symptoms of chronic military service-related PTSD: a randomized trial | Q38486961 | ||
| Sleep Disturbances in Depression | Q38521394 | ||
| The VA augmentation and switching treatments for improving depression outcomes (VAST-D) study: Rationale and design considerations | Q38567917 | ||
| P304 | page(s) | 450-457 | |
| P577 | publication date | 2019-04-08 | |
| P1433 | published in | Journal of Affective Disorders | Q15716493 |
| P1476 | title | Psychotropic polypharmacy reconsidered: Between-class polypharmacy in the context of multimorbidity in the treatment of depressive disorders | |
| P478 | volume | 252 |
| Q89819918 | Psychotropic Polypharmacy in Adults 55 Years or Older: A Risk for Impaired Global Cognition, Executive Function, and Mobility | cites work | P2860 |
Search more.